Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway.
PI3K inhibitor
osteoclasts
osteosarcoma
pictilisib
targeted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
10
2020
accepted:
16
12
2020
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Despite advances in neoadjuvant chemotherapy, outcomes for patients with osteosarcoma resistant to first-line chemotherapy have been dismal for decades. There is thus an urgent need to develop novel targeted drugs to effectively treat refractory osteosarcoma. Dysregulation in the PI3K/AKT pathway has been observed during the development of osteosarcoma. Herein, we first evaluated p-AKT (Ser473) expression levels in osteosarcoma tissue using high-throughput tissue microarrays. Then, we demonstrated the role of pictilisib, a novel potent PI3K inhibitor, in osteosarcoma and related osteolysis. Functional studies of pictilisib in osteosarcoma cell lines and bone marrow-derived macrophages were performed
Identifiants
pubmed: 33659212
doi: 10.3389/fonc.2020.615146
pmc: PMC7917262
doi:
Types de publication
Journal Article
Langues
eng
Pagination
615146Informations de copyright
Copyright © 2021 Liang, Yu, Xiong, Zhang, Sun and Dong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 2007 Aug 1;67(15):7308-18
pubmed: 17671200
Cancer Res. 2019 Jan 1;79(1):7-20
pubmed: 30389703
J Med Chem. 2008 Sep 25;51(18):5522-32
pubmed: 18754654
J Recept Signal Transduct Res. 2015;35(6):640-5
pubmed: 26390889
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
BMC Med Genomics. 2014 Jan 21;7:4
pubmed: 24447333
Cancer Biol Ther. 2015;16(4):602-9
pubmed: 25869769
Int J Oncol. 2008 Dec;33(6):1231-8
pubmed: 19020756
Curr Drug Targets. 2021;22(1):77-104
pubmed: 32914712
Front Pharmacol. 2020 Apr 02;11:389
pubmed: 32300300
Bonekey Rep. 2013 Jul 17;2:378
pubmed: 24422100
Paediatr Drugs. 2008;10(5):315-27
pubmed: 18754698
Bone. 2005 Jul;37(1):74-86
pubmed: 15894525
Eur J Pharmacol. 2018 Sep 5;834:188-196
pubmed: 30031797
Oncol Lett. 2020 Aug;20(2):1001-1014
pubmed: 32724339
Cell Mol Life Sci. 2015 Aug;72(16):3097-113
pubmed: 25935149
Trends Endocrinol Metab. 2012 Nov;23(11):582-90
pubmed: 22705116
Epigenomics. 2019 Nov 1;11(15):1693-1715
pubmed: 31650864
J Adolesc Young Adult Oncol. 2017 Sep;6(3):396-405
pubmed: 28263668
Cancer Res. 2010 Feb 1;70(3):1164-72
pubmed: 20103642
Clin Cancer Res. 2015 Jan 1;21(1):77-86
pubmed: 25370471
Oncol Lett. 2017 Dec;14(6):6749-6753
pubmed: 29151914
Biochim Biophys Acta. 2012 Dec;1826(2):434-42
pubmed: 22846337
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73
pubmed: 25512523
Breast Cancer Res. 2018 Sep 5;20(1):109
pubmed: 30185228
Cancer Lett. 2014 Mar 28;344(2):291-8
pubmed: 24333720
Clin Orthop Relat Res. 2008 Sep;466(9):2114-30
pubmed: 18563507
Clin Chim Acta. 2015 Apr 15;444:182-92
pubmed: 25704303
Lancet Oncol. 2019 Dec;20(12):1719-1729
pubmed: 31704134
Clin Cancer Res. 2017 Nov 1;23(21):6580-6591
pubmed: 28808038
Nature. 2006 May 18;441(7091):366-70
pubmed: 16625210
Curr Pharm Des. 2010;16(27):2981-7
pubmed: 20722622
Int J Mol Sci. 2020 Sep 19;21(18):
pubmed: 32961800
Cancer Treat Res. 2009;152:3-13
pubmed: 20213383
J Immunol. 2012 Jan 1;188(1):163-9
pubmed: 22131333